CLINICAL_TRIALS
trial_result
· 2012-11-16
Clinical Trial Update: A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1) [Phase 3]
Summary
Pfizer terminated a Phase 3 trial evaluating PD 0332334 for generalized anxiety disorder.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: TERMINATED